First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies.
Saved in:
| Title: | First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies. |
|---|---|
| Authors: | Naing A; Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA anaing@mdanderson.org., Lin CC; National Taiwan University Hospital, Taipei City, Taiwan., Patel MR; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida, USA., Curigliano G; Istituto Europeo di Oncologia Biblioteca IRCCS, Milan, Lombardy, Italy.; Medical Oncology and Hematology Department, University of Milan, Milan, Lombardy, Italy., Burris HA; Sarah Cannon Research Institute LLC, Nashville, Tennessee, USA., Thistlethwaite F; Advanced Immunotherapy and Cell Therapy Team, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK., De Braud F; Medical Oncology and Hematology Department, University of Milan, Milan, Lombardy, Italy.; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy., Minchom A; Drug Development Unit, Royal Marsden Hospital, The Institute of Cancer Research - Sutton, London, UK., Ascierto PA; Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.; Universita degli Studi di Napoli Federico II, Naples, Campania, Italy., Wake M; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Nguyen MA; Sanofi, Frankfurt, Germany., Abbadessa G; Sanofi, Research and Development, Sanofi, Morristown, New Jersey, USA., Sainson RCA; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Palu CC; Sanofi, Cambridge, UK., Quaratino S; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK., Deantonio C; Sanofi, Cambridge, UK. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Jun 08; Vol. 14 (6). Date of Electronic Publication: 2026 Jun 08. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42259602 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Naing+A%22">Naing A</searchLink>; Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA anaing@mdanderson.org.<br /><searchLink fieldCode="AU" term="%22Lin+CC%22">Lin CC</searchLink>; National Taiwan University Hospital, Taipei City, Taiwan.<br /><searchLink fieldCode="AU" term="%22Patel+MR%22">Patel MR</searchLink>; Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida, USA.<br /><searchLink fieldCode="AU" term="%22Curigliano+G%22">Curigliano G</searchLink>; Istituto Europeo di Oncologia Biblioteca IRCCS, Milan, Lombardy, Italy.; Medical Oncology and Hematology Department, University of Milan, Milan, Lombardy, Italy.<br /><searchLink fieldCode="AU" term="%22Burris+HA%22">Burris HA</searchLink>; Sarah Cannon Research Institute LLC, Nashville, Tennessee, USA.<br /><searchLink fieldCode="AU" term="%22Thistlethwaite+F%22">Thistlethwaite F</searchLink>; Advanced Immunotherapy and Cell Therapy Team, Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22De+Braud+F%22">De Braud F</searchLink>; Medical Oncology and Hematology Department, University of Milan, Milan, Lombardy, Italy.; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy.<br /><searchLink fieldCode="AU" term="%22Minchom+A%22">Minchom A</searchLink>; Drug Development Unit, Royal Marsden Hospital, The Institute of Cancer Research - Sutton, London, UK.<br /><searchLink fieldCode="AU" term="%22Ascierto+PA%22">Ascierto PA</searchLink>; Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.; Universita degli Studi di Napoli Federico II, Naples, Campania, Italy.<br /><searchLink fieldCode="AU" term="%22Wake+M%22">Wake M</searchLink>; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Nguyen+MA%22">Nguyen MA</searchLink>; Sanofi, Frankfurt, Germany.<br /><searchLink fieldCode="AU" term="%22Abbadessa+G%22">Abbadessa G</searchLink>; Sanofi, Research and Development, Sanofi, Morristown, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Sainson+RCA%22">Sainson RCA</searchLink>; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Palu+CC%22">Palu CC</searchLink>; Sanofi, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Quaratino+S%22">Quaratino S</searchLink>; Kymab, a Sanofi Company, Babraham Research Campus, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Deantonio+C%22">Deantonio C</searchLink>; Sanofi, Cambridge, UK. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2026 Jun 08; Vol. 14 (6). <i>Date of Electronic Publication: </i>2026 Jun 08. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase I – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42259602 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1136/jitc-2025-013540 Languages: – Code: eng Text: English Titles: – TitleFull: First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignancies. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Naing A – PersonEntity: Name: NameFull: Lin CC – PersonEntity: Name: NameFull: Patel MR – PersonEntity: Name: NameFull: Curigliano G – PersonEntity: Name: NameFull: Burris HA – PersonEntity: Name: NameFull: Thistlethwaite F – PersonEntity: Name: NameFull: De Braud F – PersonEntity: Name: NameFull: Minchom A – PersonEntity: Name: NameFull: Ascierto PA – PersonEntity: Name: NameFull: Wake M – PersonEntity: Name: NameFull: Nguyen MA – PersonEntity: Name: NameFull: Abbadessa G – PersonEntity: Name: NameFull: Sainson RCA – PersonEntity: Name: NameFull: Palu CC – PersonEntity: Name: NameFull: Quaratino S – PersonEntity: Name: NameFull: Deantonio C IsPartOfRelationships: – BibEntity: Dates: – D: 08 M: 06 Text: 2026 Jun 08 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2051-1426 Numbering: – Type: volume Value: 14 – Type: issue Value: 6 Titles: – TitleFull: Journal for immunotherapy of cancer Type: main |
| ResultId | 1 |
